This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Adjunct amniotic membrane during enucleation for retinoblastoma to prevent implant exposure

Adjunct amniotic membrane during enucleation for retinoblastoma to prevent implant exposure
Reviewed by Fiona Rowe

28 February 2025 | Fiona Rowe (Prof) | EYE - Paediatrics
Share This

Amniotic membrane (AM) has potential for treatment of retinoblastoma (RB) patients with contracted sockets after enucleation. The authors present their experience of AM with enucleation for patients with RB after chemotherapy in this retrospective study of 100 eyes of 107 patients. Primary enucleation was required for 77 eyes (70%) and secondary enucleation for the remainder. Systemic chemotherapy was given to 49 patients (45.7%). Other therapies included intra-arterial chemotherapy (IAT: 11.8%), intravitreal chemotherapy (3.6%), subconjunctival chemotherapy (1.8%), plaque brachytherapy (2.7%) and external beam radiation therapy (EBRT: 6.3%). Amniotic membrane graft was used in eight eyes during enucleation and none had implant exposure or wound infection, with average follow-up of 108 weeks (range 40–148). IAC was found to be a significant risk factor for implant exposure. All exposures were in children who did not have a simultaneous AM placement. Advantages reported for AM use were that it is easily available, transparent, non-immunogenic, and has antifibrotic effects and anti-inflammatory effects with improved postoperative healing. Disadvantages are that AM is a biological membrane, is not strong tectonically, and is thin and fragile. The authors conclude AM is a useful adjunct during enucleation surgery to prevent implant extrusion and is of particular benefit for those who receive chemotherapy.

Amniotic membrane augmentation for enucleation after chemotherapy in retinoblastoma.
Ramasubramanian A, Rahman NS, Chauhan A, et al.
JOURNAL OF PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
2024;61(4):291–5.
Share This
Fiona Rowe (Prof)
CONTRIBUTOR
Fiona Rowe (Prof)

Institute of Population Health, University of Liverpool, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency